Cencora, Inc.

Pharmaceutical distribution volume is driven by prescription demand that has grown without interruption across FY2020-FY2025, including through the COVID period. Multi-year contracts with major retail chains, hospital systems, and specialty physician offices provide structural revenue continuity, and renewal rates have historically remained high across the customer base.

Cencora distributes branded, generic, specialty, and biosimilar drugs across retail pharmacy, hospital, and physician-office channels, adding breadth within pharmaceuticals. All revenue ultimately stems from drug distribution and adjacent managed services, concentrating the business on a single industry with limited exposure to genuinely uncorrelated product categories.

U.S. Healthcare Solutions generated approximately $285 billion of $321 billion in fiscal 2025 revenue, leaving international operations at roughly 11%, concentrated in Europe through Alliance Healthcare. Asia-Pacific and Latin American exposure is minimal, making the business heavily dependent on U.S. drug volumes and domestic healthcare policy.

Drug distribution is a high-throughput, low-margin operation requiring physical distribution centers, temperature-controlled logistics, and proportional operating costs as volumes rise. Specialty distribution and managed services (OneOncology) offer better operating leverage, but they remain a modest share of total revenue and do not materially alter the overall cost structure.

Prescription drugs are non-discretionary, making demand structurally defensive regardless of economic conditions. Revenue is earned per unit distributed on multi-year contracts rather than fixed subscriptions, leaving it volume-dependent, though the essential nature of drug supply and high customer retention produce consistent annual throughput.